Inhibitory effect of carvedilol on human hepatic stellate cell activation and fibrosis induced by platelet-derived growth factor-BB and related mechanisms of action
ObjectiveTo investigate the effect of carvedilol on the migration, invasion and fibrosis of human hepatic stellate cells, as well as related signaling pathways and mechanisms. MethodsHuman hepatic stellate cell line LX-2 was treated with different concentrations of carvedilol (0, 1, 2, 5, and 10 μmo...
Main Authors: | , |
---|---|
Format: | Article |
Language: | zho |
Published: |
Editorial Department of Journal of Clinical Hepatology
2017-03-01
|
Series: | Linchuang Gandanbing Zazhi |
Subjects: | |
Online Access: | http://www.lcgdbzz.org/qk_content.asp?id=8067 |
id |
doaj-461778136940427bbf2e8fc651574336 |
---|---|
record_format |
Article |
spelling |
doaj-461778136940427bbf2e8fc6515743362020-11-25T00:08:06ZzhoEditorial Department of Journal of Clinical HepatologyLinchuang Gandanbing Zazhi1001-52561001-52562017-03-0133348549110.3969/j.issn.1001-5256.2017.03.018Inhibitory effect of carvedilol on human hepatic stellate cell activation and fibrosis induced by platelet-derived growth factor-BB and related mechanisms of actionLI Zhen0LIU Bin1Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong UniversityDepartment of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong UniversityObjectiveTo investigate the effect of carvedilol on the migration, invasion and fibrosis of human hepatic stellate cells, as well as related signaling pathways and mechanisms. MethodsHuman hepatic stellate cell line LX-2 was treated with different concentrations of carvedilol (0, 1, 2, 5, and 10 μmol/L, and platelet-derived growth factor-BB (PDGF-BB) was added to activate the cells. CCK-8 assay was used to measure cell proliferation, wound healing assay was used to measure migration, Transwell chamber assay was used to measure invasion, and Western blot and real-time PCR were used to measure the protein and mRNA expression of fibrosis markers and pathway proteins. The cells were divided into blank control group, PDGF-BB group (only PDGF-BB was added), and four carvedilol groups (with 1, 2, 5, or 10 μmol/L carvedilol, as well as PDGF-BB). A one-way analysis of variance was used for comparison of continuous data between multiple groups, and the Dunnett-t test was used for comparison between experimental groups and control group. ResultsCarvedilol inhibited the proliferation of LX-2 cells in a concentration-dependent manner, with a half-inhibitory concentration of 28.42 μmol/L. Compared with the PDGF-BB group, the 10 μmol/L carvedilol group had significantly inhibited migration of LX-2 cells (59.780%±8.898% vs 17.270%±2.668%, t=4.576, P=0.010). PDGF-BB increased the invasion of LX-2 cells, and carvedilol inhibited the invasion of LX-2 cells in a concentration-dependent manner; the invasion of LX-2 cells was reduced from 157.00%±1052% to 8515%±1350% in the 2 μmol/L carvedilol group (t=4198, P=0014), to 5567%±954% in the 5 μmol/L carvedilol group (t=7133, P<001), and to 4537%±1070% in the 10 μmol/L carvedilol group (t=7438, P<001) The mRNA expression of type I collagen was reduced from 1068±0128 to 0453±0085 in the 5 μmol/L carvedilol group (t=3997, P<005) and to 0151±0019 in the 10 μmol/L carvedilol group (t=7091, P<001) The mRNA expression of fibronectin was reduced from 1285±0042 to 0879±0063 in the 1 μmol/L carvedilol group (t=5345, P<001), to 0768±0010 in the 2 μmol/L carvedilol group (t=4773, P<001), to 0742±0117 in the 5 μmol/L carvedilol group (t=4385, P=0012), and to 0591±0049 in the 10 μmol/L carvedilol group (t=1076, P<001) The expression of fibronectin was reduced from 2103±0414 to 0739±0132 in the 5 μmol/L carvedilol group (t=3137, P=0035) and to 0600±0114 in the 10 μmol/L carvedilol group (t=3499, P=0025), and the expression of α-smooth muscle actin was reduced from 1418±0241 to 0543±0215 (t=2710, P=0035) and 0343±0118 (t=4005, P<001), respectively Y751 phosphorylation was reduced from 2309±0181 to 1278±0304 in the 2 μmol/L carvedilol group (t=2912, P=0044), to 0555±0038 in the 5 μmol/L carvedilol group (t=9476, P<001), and to 0175±0039 in the 10 μmol/L group (t=1151, P<001) Akt phosphorylation was reduced from 1106±0185 to 0335±0132 in the 5 μmol/L carvedilol group (t=3386, P=0015) and to 0137±0110 in the 10 μmol/L carvedilol group (t=4494, P<001). ConclusionCarvedilol can inhibit the proliferation, migration, invasion, and fibrosis of LX-2 cells induced by PDGF-BB, mainly by blocking the PDGF-BB/PDGFR-β/Akt signaling pathway.http://www.lcgdbzz.org/qk_content.asp?id=8067carvedilolhepatic stellate cellsliver cirrhosis |
collection |
DOAJ |
language |
zho |
format |
Article |
sources |
DOAJ |
author |
LI Zhen LIU Bin |
spellingShingle |
LI Zhen LIU Bin Inhibitory effect of carvedilol on human hepatic stellate cell activation and fibrosis induced by platelet-derived growth factor-BB and related mechanisms of action Linchuang Gandanbing Zazhi carvedilol hepatic stellate cells liver cirrhosis |
author_facet |
LI Zhen LIU Bin |
author_sort |
LI Zhen |
title |
Inhibitory effect of carvedilol on human hepatic stellate cell activation and fibrosis induced by platelet-derived growth factor-BB and related mechanisms of action |
title_short |
Inhibitory effect of carvedilol on human hepatic stellate cell activation and fibrosis induced by platelet-derived growth factor-BB and related mechanisms of action |
title_full |
Inhibitory effect of carvedilol on human hepatic stellate cell activation and fibrosis induced by platelet-derived growth factor-BB and related mechanisms of action |
title_fullStr |
Inhibitory effect of carvedilol on human hepatic stellate cell activation and fibrosis induced by platelet-derived growth factor-BB and related mechanisms of action |
title_full_unstemmed |
Inhibitory effect of carvedilol on human hepatic stellate cell activation and fibrosis induced by platelet-derived growth factor-BB and related mechanisms of action |
title_sort |
inhibitory effect of carvedilol on human hepatic stellate cell activation and fibrosis induced by platelet-derived growth factor-bb and related mechanisms of action |
publisher |
Editorial Department of Journal of Clinical Hepatology |
series |
Linchuang Gandanbing Zazhi |
issn |
1001-5256 1001-5256 |
publishDate |
2017-03-01 |
description |
ObjectiveTo investigate the effect of carvedilol on the migration, invasion and fibrosis of human hepatic stellate cells, as well as related signaling pathways and mechanisms. MethodsHuman hepatic stellate cell line LX-2 was treated with different concentrations of carvedilol (0, 1, 2, 5, and 10 μmol/L, and platelet-derived growth factor-BB (PDGF-BB) was added to activate the cells. CCK-8 assay was used to measure cell proliferation, wound healing assay was used to measure migration, Transwell chamber assay was used to measure invasion, and Western blot and real-time PCR were used to measure the protein and mRNA expression of fibrosis markers and pathway proteins. The cells were divided into blank control group, PDGF-BB group (only PDGF-BB was added), and four carvedilol groups (with 1, 2, 5, or 10 μmol/L carvedilol, as well as PDGF-BB). A one-way analysis of variance was used for comparison of continuous data between multiple groups, and the Dunnett-t test was used for comparison between experimental groups and control group. ResultsCarvedilol inhibited the proliferation of LX-2 cells in a concentration-dependent manner, with a half-inhibitory concentration of 28.42 μmol/L. Compared with the PDGF-BB group, the 10 μmol/L carvedilol group had significantly inhibited migration of LX-2 cells (59.780%±8.898% vs 17.270%±2.668%, t=4.576, P=0.010). PDGF-BB increased the invasion of LX-2 cells, and carvedilol inhibited the invasion of LX-2 cells in a concentration-dependent manner; the invasion of LX-2 cells was reduced from 157.00%±1052% to 8515%±1350% in the 2 μmol/L carvedilol group (t=4198, P=0014), to 5567%±954% in the 5 μmol/L carvedilol group (t=7133, P<001), and to 4537%±1070% in the 10 μmol/L carvedilol group (t=7438, P<001) The mRNA expression of type I collagen was reduced from 1068±0128 to 0453±0085 in the 5 μmol/L carvedilol group (t=3997, P<005) and to 0151±0019 in the 10 μmol/L carvedilol group (t=7091, P<001) The mRNA expression of fibronectin was reduced from 1285±0042 to 0879±0063 in the 1 μmol/L carvedilol group (t=5345, P<001), to 0768±0010 in the 2 μmol/L carvedilol group (t=4773, P<001), to 0742±0117 in the 5 μmol/L carvedilol group (t=4385, P=0012), and to 0591±0049 in the 10 μmol/L carvedilol group (t=1076, P<001) The expression of fibronectin was reduced from 2103±0414 to 0739±0132 in the 5 μmol/L carvedilol group (t=3137, P=0035) and to 0600±0114 in the 10 μmol/L carvedilol group (t=3499, P=0025), and the expression of α-smooth muscle actin was reduced from 1418±0241 to 0543±0215 (t=2710, P=0035) and 0343±0118 (t=4005, P<001), respectively Y751 phosphorylation was reduced from 2309±0181 to 1278±0304 in the 2 μmol/L carvedilol group (t=2912, P=0044), to 0555±0038 in the 5 μmol/L carvedilol group (t=9476, P<001), and to 0175±0039 in the 10 μmol/L group (t=1151, P<001) Akt phosphorylation was reduced from 1106±0185 to 0335±0132 in the 5 μmol/L carvedilol group (t=3386, P=0015) and to 0137±0110 in the 10 μmol/L carvedilol group (t=4494, P<001). ConclusionCarvedilol can inhibit the proliferation, migration, invasion, and fibrosis of LX-2 cells induced by PDGF-BB, mainly by blocking the PDGF-BB/PDGFR-β/Akt signaling pathway. |
topic |
carvedilol hepatic stellate cells liver cirrhosis |
url |
http://www.lcgdbzz.org/qk_content.asp?id=8067 |
work_keys_str_mv |
AT lizhen inhibitoryeffectofcarvedilolonhumanhepaticstellatecellactivationandfibrosisinducedbyplateletderivedgrowthfactorbbandrelatedmechanismsofaction AT liubin inhibitoryeffectofcarvedilolonhumanhepaticstellatecellactivationandfibrosisinducedbyplateletderivedgrowthfactorbbandrelatedmechanismsofaction |
_version_ |
1725416753164451840 |